Quick Answer
MAIA Biotechnology, Inc. reported Diluted EPS of $0.70 per share (loss) for fiscal year 2025.
MAIA Biotechnology, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.70 | +33.3% |
| 2024 | -$1.05 | +29.5% |
| 2023 | -$1.49 | +14.9% |
| 2022 | -$1.75 | +26.2% |
| 2021 | -$2.37 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.27 | -145.5% | -50.0% |
| June 30, 2025 | -$0.18 | +55.0% | -12.5% |
| March 31, 2025 | -$0.16 | +65.2% | -45.5% |
| September 30, 2024 | -$0.11 | +69.4% | +72.5% |
| June 30, 2024 | -$0.40 | -14.3% | +13.0% |
| March 31, 2024 | -$0.46 | -21.1% | -27.8% |
| September 30, 2023 | -$0.36 | +25.0% | -2.9% |
| June 30, 2023 | -$0.35 | +12.5% | +7.9% |
- MAIA Biotechnology, Inc. showed an increase of +33.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, MAIA Biotechnology, Inc.’s diluted eps has grown by 70.5% (from $2.37 per share (loss) to $0.70 per share (loss)).
- The most recent figure is from MAIA Biotechnology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: